Specificity of transcranial sonography in parkinson spectrum disorders in comparison to degenerative cognitive syndromes

BMC Neurology

Volumn 12, Issue , 2012, Pages

  Laučkaite, Kristina ^a   Rastenyte, Daiva ^a   Šurkiene, Danguole ^a   Vaitkus, Antanas ^a   Sakalauskas, Andrius ^b   Lukoševičius, Arunas ^b   Gleizniene, Rymante ^a  

^a LITHUANIAN UNIVERSITY OF HEALTH SCIENCES   (Lithuania)

^b KAUNAS UNIVERSITY OF TECHNOLOGY   (Lithuania)

Author keywords

Cognitive disorders; Parkinson's disease; Sensitivity; Specificity; Substantia nigra; Transcranial sonography

Indexed keywords

AGED; ARTICLE; ATYPICAL PARKINSONIAN SYNDROME; B SCAN; CLINICAL EXAMINATION; CONTROLLED STUDY; DEGENERATIVE DISEASE; DEMENTIA; DIAGNOSTIC ACCURACY; DOPPLER ECHOGRAPHY; ESSENTIAL TREMOR; FEMALE; HEREDITARY NEURODEGENERATIVE PARKINSONISM; HUMAN; IMAGE QUALITY; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; NEUROIMAGING; PARKINSON DISEASE; PARKINSONISM; PROSPECTIVE STUDY; SECONDARY PARKINSONISM; SENSITIVITY AND SPECIFICITY; TRANSCRANIAL B MODE DUPLEX SONOGRAPHY; CASE CONTROL STUDY; COMPARATIVE STUDY; ECHOGRAPHY; MIDDLE AGED; PREDICTIVE VALUE; SUBSTANTIA NIGRA;

AGED; CASE-CONTROL STUDIES; DEMENTIA; ESSENTIAL TREMOR; FEMALE; HUMANS; MALE; MIDDLE AGED; MILD COGNITIVE IMPAIRMENT; PARKINSON DISEASE; PARKINSON DISEASE, SECONDARY; PARKINSONIAN DISORDERS; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; SUBSTANTIA NIGRA;

EID: 84859428783     PISSN: None     EISSN: 14712377     Source Type: Journal    
DOI: 10.1186/1471-2377-12-12     Document Type: Article

References (38)

1. World Health Organization Neurological disorders. Public health challenges 2007, Geneva: World Health Organization Press, World Health Organization.
2. Olanow CW, Stern MB, Sethi K. The scientific and clinical basis for the treatment of Parkinson disease. Neurology 2009, 72(Suppl4):1-136.
3. Logishetty K, Chaudhuri KR. Parkinson's disease. In Movement Disorders in Clinical Practice 2010, 1-11. London: Springer, Chaudhuri KR, Ondo WG.
4. Vlaar AM, de Nijs T, van Kroonenburgh MJPG, Mess WH, Winogrodzka A, Tromp SC, Weber WEJ. The predictive value of transcranial duplex sonography for the clinical diagnosis in undiagnosed parkinsonian syndromes: comparison with SPECT scans. BMC Neurol 2008, 8:42. 10.1186/1471-2377-8-42, 2628347, 18992168.
5. Becker G, Seufert J, Bogdahn U, Reichmann H, Reiners K. Degeneration of substantia nigra in chronic Parkinson's disease visualized by transcranial color-coded real-time sonography. Neurology 1995, 45:182-184.
6. Berg D. Substantia nigra hyperechogenicity as a risk marker for Parkinson's disease: yes. J Neural Transm 2011, 118:613-619. 10.1007/s00702-010-0565-6, 21207077.
7. Berg D, Seppi K, Behnke S, Liepelt I, Schweitzer K, Stockner H, Wollenweber F, Gaenslen A, Mahlknecht P, Spiegel J, Godau J, Huber H, Srulijes K, Kiechl S, Bentele M, Gasperi A, Schubert T, Hiry T, Probst M, Schneider V, Klenk J, Sawires M, Willeit J, Maetzler W, Fassbender K, Gasser T, Poewe W. Enlarged substantia nigra echogenicity and risk for Parkinson disease: a 37-month 3-centre study of 1847 older persons. Arch Neurol 2011, 68:932-937. 10.1001/archneurol.2011.141, 21747034.
8. Hoeppner J, Prudente-Morrissey L, Herpertz SC, Benecke R, Walter U. Substantia nigra hyperechogenicity in depressive subjects relates to motor asymmetry and impaired word fluency. Eur Arch Psychiatry Clin Neurosci 2009, 259:92-97. 10.1007/s00406-008-0840-9, 18806917.
9. Walter U. Substantia nigra hyperechogenicity is a risk marker of Parkinson's disease: no. J Neural Transm 2011, 118:607-612. 10.1007/s00702-010-0564-7, 21190047.
10. Hagenah J, König IR, Sperner J, Wessel L, Seidel G, Condefer K, Saunders-Pullman R, Klein CH, Brüggemann N. Life-long increase of substantia nigra hyperechogenicity in transcranial sonography. NeuroImage 2010, 51:28-32. 10.1016/j.neuroimage.2010.01.112, 20152909.
11. Behnke S, Double KL, Duma S, Broe GA, Guenther V, Becker G, Halliday GM. Substantia nigra echomorphology in the healthy very old: correlation with motor slowing. NeuroImage 2007, 34:1054-1059. 10.1016/j.neuroimage.2006.10.010, 17141529.
12. Mehnert S, Reuter I, Schepp K, Maaser P, Stolz E, Kaps M. Transcranial sonography for diagnosis of Parkinson's disease. BMC Neurol 2010, 10:9. 10.1186/1471-2377-10-9, 2822767, 20089201.
13. Prestel J, Schweitzer KJ, Hofer A, Gasser T, Berg D. Predictive value of transcranial sonography in the diagnosis of Parkinson's disease. Mov Disord 2006, 21:1763-1765. 10.1002/mds.21054, 16874758.
14. Doepp F, Plotkin M, Siegel L, Kivi A, Gruber D, Lobsien E, Kupsch A, Schreiber SJ. Brain parenchyma sonography and 123I-FP-CIT SPECT in Parkinson's disease and essential tremor. Mov Disord 2008, 23:405-410. 10.1002/mds.21861, 18067184.
15. Stockner H, Sojer M, KS K, Mueller J, Wenning GK, Schmidauer C, Poewe W. Midbrain sonography in patients with essential tremor. Mov Disord 2007, 22:414-417. 10.1002/mds.21344, 17226854.
16. Ressner P, Skoloudik D, Hlustik P, Kanovsky P. Hyperechogenicity of the substantia nigra in Parkinson's disease. J Neuroimaging 2007, 17:164-167. 10.1111/j.1552-6569.2007.00114.x, 17441838.
17. Huang YW, Jeng JS, Tsai CF, Chen LL, Wu RM. Trancranial imaging of substantia nigra hyperechogenicity in a Taiwanese cohort of Parkinson disease. Mov Disord 2007, 22:187-192. 10.1002/mds.21230, 17133515.
18. Hagenah JM, König IR, Becker B, Hilker R, Kasten M, Hedrich K, Pramstaller P, Klein C, Seidel G. Substantia nigra hyperechogenicity correlates with clinical status and number of Parkin mutated alleles. J Neurol 2007, 254:1407-1413. 10.1007/s00415-007-0567-y, 17934880.
19. Schweitzer KJ, Behnke S, Liepelt I, Wolf B, Grosser C, Godau J, Gaenslen A, Bruessel T, Wendt A, Abel F, Müller A, Gasser T, Berg D. Cross-sectional study discloses a positive family history for Parkinson's disease and male gender as epidemiological risk factors for substantia nigra hyperechogenicity. J Neural Transm 2007, 114:1167-1171. 10.1007/s00702-007-0725-5, 17446999.
20. Kim JY, Kim ST, Jeon SH, Lee WY. Midbrain transcranial sonography in Korean patients with Parkinson's disease. Mov Disord 2007, 22:1922-1926. 10.1002/mds.21628, 17588240.
21. Budisic M, Trkanjec Z, Bosnjak J, Lovrencic-Huzjan A, Vukovic V, Demarin V. Distinguishing Parkinson's disease and essential tremor with transcranial sonography. Acta Neurol Scand 2009, 119:17-21. 10.1111/j.1600-0404.2008.01056.x, 18549415.
22. Van DL, Walter U, Behnke S, Hagenah J, Lorenz M, Sitzer M, Hilker R, Berg D. Reproducibility and diagnostic accuracy of substantia nigra sonography for the diagnosis of Parkinson's disease. J Neurol Neurosurg Psychiatry 2010, 81(10):1087-1092. 10.1136/jnnp.2009.196352, 20543186.
23. Behnke S, Berg D, Naumann M, Becker G. Differentiation of Parkinson's disease and atypical parkinsonian syndromes by transcranial ultrasound. J Neurol Neurosurg Psychiatry 2005, 76(3):423-425. 10.1136/jnnp.2004.049221, 1739539, 15716540.
24. Gaenslen A, Unmuth B, Godau J, Liepelt I, Santo D, Schweitzer KJ, Gasser T, Machulla H-J, Reimold M, Marek K, Berg D. The specificity and sensitivity of transcranial ultrasound in the differential diagnosis of Parkinson's disease: a prospective blinded study. Lancet Neurol 2008, 7:417-424. 10.1016/S1474-4422(08)70067-X, 18394965.
25. Walter U, Niehaus L, Probst T, Benecke R, Meyer BU, Dressler D. Brain parenchyma sonography discriminates Parkinson's disease and atypical parkinsonian syndromes. Neurology 2003, 60:74-77.
26. Tsai SF, Wu RM, Huang YW, Chen LL, Yip PK, Jeng JS. Transcranial color-coded sonography helps differentiation between idiopathic Parkinson's disease and vascular parkinsonism. J Neurol 2007, 254:501-507. 10.1007/s00415-006-0403-9, 17401518.
27. Okawa M, Miwa H, Kajimoto Y, Hama K, Morita S, Nakanishi I, Kondo T. Transcranial sonography of substantia nigra in Japanese patients with Parkinson's disease or atypical parkinsonism: clinical potential and limitations. Intern Med 2007, 46(18):1527-1531. 10.2169/internalmedicine.46.0271, 17878638.
28. Gibb WR, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 1988, 51:745-752. 10.1136/jnnp.51.6.745, 1033142, 2841426.
29. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983, 67:361-370. 10.1111/j.1600-0447.1983.tb09716.x, 6880820.
30. Fahn S, Elton RL, . Members of the UPDRS Development Committee The Unified Parkinson's Disease Rating Scale. Recent developments in Parkinson's disease 1987, 2:153-163. Florham Park, NJ: Macmillan Health Care Information, Fahn S, Marsden CD, Calne DB, Goldstein M, Members of the UPDRS Development Committee.
31. Folstein MF, Folstein SE, McHugh PR. Mini-mental state. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975, 12:189-198. 10.1016/0022-3956(75)90026-6, 1202204.
32. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry 1984, 141(11):1356-1364.
33. Sakalauskas A, Lukoševičius A, Laučkaitė K. Transcranial echoscopy for diagnostic of Parkinson disease: technical constraints and possibilities. Ultragarsas 2010, 65:47-50.
34. Walter U, Behnke S, Eyding J, Niehaus L, Postert T, Seidel G, Berg D. Transcranial brain parenchyma sonography in movement disorders: state of the art. Ultrasound Med Biol 2007, 33:15-25. 10.1016/j.ultrasmedbio.2006.07.021, 17189043.
35. Bártová P, Školoudík D, Ressner P, Langová K, Herzig R, Kaňovský P. Correlation between substantia nigra features detected by sonography and Parkinson disease symptoms. J Ultrasound Med 2010, 29:37-42.
36. Berg D, Siefker C, Becker G. Echogenicity of the substantia nigra in Parkinson's disease and its relation to clinical findings. J Neurol 2001, 248:684-689. 10.1007/s004150170114, 11569897.
37. Spiegel J, Hellwig D, Möllers MO, Behnke S, Jost W, Fassbender K, Samnick S, Dillmann U, Becker G, Kirsch CM. Transcranial sonography and [123I]FP-CIT SPECT disclose complementary aspects of Parkinson's disease. Brain 2006, 129:1188-1193. 10.1093/brain/awl042, 16513685.
38. Berg D. Hyperechogenicity of the substantia nigra: pitfalls in assessment and specificity for Parkinson's disease. J Neural Transm 2011, 118:453-461. 10.1007/s00702-010-0469-5, 20830493.